These data are cause for concern about therapeutic strategies that boost CD4 T cell function in Mtb infection by targeting inhibitory receptors, now referred to as checkpoint blockade, and at least one report has noted TB reactivation associated with PD-1 blockade treatment of Hodgkin’s lymphoma [62]. The gene discussed is PDCD1; the disease is tuberculosis.